Page 1 | Search Results | Clinical Cancer Research | American Association for Cancer Research

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations

Daniel A. Pollyea, Courtney D. DiNardo, Martha L. Arellano, Arnaud Pigneux, Walter Fiedler, Marina Konopleva, David A. Rizzieri, B. Douglas Smith, Atsushi Shinagawa, Roberto M. Lemoli, Monique Dail, Yinghui Duan, Brenda Chyla, Jalaja Potluri, Catherine L. Miller, Hagop M. Kantarjian

Clin Cancer Res (2022) 28 (13): 2753–2761.

https://doi.org/10.1158/1078-0432.CCR-21-3467

Published: 01 July 2022

View article titled, Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations

Includes: Supplementary data

Journal Articles

Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia

Marina Konopleva, Michael J. Thirman, Keith W. Pratz, Jacqueline S. Garcia, Christian Recher, Vinod Pullarkat, Hagop M. Kantarjian, Courtney D. DiNardo, Monique Dail, Yinghui Duan, Brenda Chyla, Jalaja Potluri, Catherine L. Miller, Andrew H. Wei

Clin Cancer Res (2022) 28 (13): 2744–2752.

https://doi.org/10.1158/1078-0432.CCR-21-3405

Published: 01 July 2022

View article titled, Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia

Includes: Supplementary data

Journal Articles

Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22

Hagop M. Kantarjian, Wendy Stock, Ryan D. Cassaday, Daniel J. DeAngelo, Elias Jabbour, Susan M. O'Brien, Matthias Stelljes, Tao Wang, M. Luisa Paccagnella, Kevin Nguyen, Barbara Sleight, Erik Vandendries, Alexander Neuhof, A. Douglas Laird, Anjali S. Advani

Clin Cancer Res (2021) 27 (10): 2742–2754.

https://doi.org/10.1158/1078-0432.CCR-20-2399

Published: 15 May 2021

View article titled, Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22

Includes: Supplementary data

Journal Articles

Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS

Michael R. Savona, Daniel A. Pollyea, Wendy Stock, Vivian G. Oehler, Mark A. Schroeder, Jeffrey Lancet, James McCloskey, Hagop M. Kantarjian, Weidong Wendy Ma, M. Naveed Shaik, A. Douglas Laird, Mirjana Zeremski, Ashleigh O'Connell, Geoffrey Chan, Jorge E. Cortes

Clin Cancer Res (2018) 24 (10): 2294–2303.

https://doi.org/10.1158/1078-0432.CCR-17-2824

Published: 14 May 2018

View article titled, Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS

Includes: Supplementary data

Journal Articles

Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia

Clin Cancer Res (2017) 23 (13): 3385–3395.

https://doi.org/10.1158/1078-0432.CCR-16-1904

Published: 02 July 2017

View article titled, Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia

Includes: Supplementary data

Journal Articles

Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

Clin Cancer Res (2017) 23 (11): 2891–2904.

https://doi.org/10.1158/1078-0432.CCR-16-1025

Published: 31 May 2017

View article titled, Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

Includes: Supplementary data

Journal Articles

The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases

David J. Stewart, Gerald Batist, Hagop M. Kantarjian, John-Peter Bradford, Joan H. Schiller, Razelle Kurzrock

Clin Cancer Res (2015) 21 (20): 4561–4568.

https://doi.org/10.1158/1078-0432.CCR-14-3246

Published: 14 October 2015

View article titled, The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases

Journal Articles

Abstract B22: Genome-wide methylation analysis reveals an independently validated CpG island methylator phenotype associated with favorable prognosis in acute myeloid leukemia.

Andrew D. Kelly, Heike Kroeger, Jumpei Yamazaki, Rodolphe Taby, Frank Neumann, Justin T. Lee, Rong He, Shoudan Liang, Yue Lu, Matteo Cesaroni, Sherry A. Pierce, Steven M. Kornblau, Carlos E. Bueso-Ramos, Farhad Ravandi, Hagop M. Kantarjian, Jean-Pierre J. Issa, Jaroslav Jelinek

Clin Cancer Res (2015) 21 (17_Supplement): B22.

https://doi.org/10.1158/1557-3265.HEMMAL14-B22

Published: 19 August 2015

View article titled, Abstract B22: Genome-wide methylation analysis reveals an independently validated CpG island methylator phenotype associated with favorable prognosis in acute myeloid leukemia.

Journal Articles

Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens

Katja Karjalainen, Diana E. Jaalouk, Carlos Bueso-Ramos, Laura Bover, Yan Sun, Akihiko Kuniyasu, Wouter H.P. Driessen, Marina Cardó-Vila, Cecilia Rietz, Amado J. Zurita, Susan O'Brien, Hagop M. Kantarjian, Jorge E. Cortes, George A. Calin, Erkki Koivunen, Wadih Arap, Renata Pasqualini

Clin Cancer Res (2015) 21 (13): 3041–3051.

https://doi.org/10.1158/1078-0432.CCR-13-3059

Published: 30 June 2015

View article titled, Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens

Includes: Supplementary data

Journal Articles

Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia

Clin Cancer Res (2014) 20 (8): 2226–2235.

https://doi.org/10.1158/1078-0432.CCR-13-1978

Published: 15 April 2014

View article titled, Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia

Includes: Supplementary data

Journal Articles

The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia

Hun Ju Lee, Naval Daver, Hagop M. Kantarjian, Srdan Verstovsek, Farhad Ravandi

Clin Cancer Res (2013) 19 (2): 327–335.

https://doi.org/10.1158/1078-0432.CCR-12-2087

Published: 16 January 2013

View article titled, The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia

Journal Articles

Second-Generation Tyrosine Kinase Inhibitors: The Future of Frontline CML Therapy

Hagop M. Kantarjian, Michele Baccarani, Elias Jabbour, Giuseppe Saglio, Jorge E. Cortes

Clin Cancer Res (2011) 17 (7): 1674–1683.

https://doi.org/10.1158/1078-0432.CCR-10-2922

Published: 31 March 2011

View article titled, Second-Generation Tyrosine Kinase Inhibitors: The Future of Frontline CML Therapy

Journal Articles

Targeting DNA Methylation

Jean-Pierre J. Issa, Hagop M. Kantarjian

Clin Cancer Res (2009) 15 (12): 3938–3946.

https://doi.org/10.1158/1078-0432.CCR-08-2783

Published: 15 June 2009

View article titled, Targeting DNA Methylation

Journal Articles

The Prognostic Significance of Serum β₂ Microglobulin Levels in Acute Myeloid Leukemia and Prognostic Scores Predicting Survival: Analysis of 1,180 Patients

Apostolia-Maria Tsimberidou, Hagop M. Kantarjian, Sijin Wen, Susan O'Brien, Jorge Cortes, William G. Wierda, Charles Koller, Sherry Pierce, Mark Brandt, Emil J. Freireich, Michael J. Keating, Elihu H. Estey

Clin Cancer Res (2008) 14 (3): 721–730.

https://doi.org/10.1158/1078-0432.CCR-07-2063

Published: 01 February 2008

View article titled, The Prognostic Significance of Serum β2 Microglobulin Levels in Acute Myeloid Leukemia and Prognostic Scores Predicting Survival: Analysis of 1,180 Patients

Journal Articles

Phase I Study of Alternate-Week Administration of Tipifarnib in Patients with Myelodysplastic Syndrome

Razelle Kurzrock, Hagop M. Kantarjian, Michelle A. Blascovich, Cindy Bucher, Srdan Verstovsek, John J. Wright, Susan R. Pilat, Jorge E. Cortes, Elihu H. Estey, Francis J. Giles, Miloslav Beran, Said M. Sebti

Clin Cancer Res (2008) 14 (2): 509–514.

https://doi.org/10.1158/1078-0432.CCR-07-1532

Published: 25 January 2008

View article titled, Phase I Study of Alternate-Week Administration of Tipifarnib in Patients with Myelodysplastic Syndrome

Journal Articles

Important Therapeutic Targets in Chronic Myelogenous Leukemia

Hagop M. Kantarjian, Francis Giles, Alfonso Quintás-Cardama, Jorge Cortes

Clin Cancer Res (2007) 13 (4): 1089–1097.

https://doi.org/10.1158/1078-0432.CCR-06-2147

Published: 22 February 2007

View article titled, Important Therapeutic Targets in Chronic Myelogenous Leukemia

Journal Articles

Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies

Clin Cancer Res (2005) 11 (18): 6615–6624.

https://doi.org/10.1158/1078-0432.CCR-05-0650

Published: 15 September 2005

View article titled, Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies

Journal Articles

Phase I Study of Oral Topotecan in Hematological Malignancies

Miloslav Beran, Susan O’Brien, Deborah A. Thomas, Hai T. Tran, Jorge E. Cortes-Franco, Francis Giles, Elihu Estey, Hagop M. Kantarjian

Clin Cancer Res (2003) 9 (11): 4084–4091.

Published: 30 September 2003

View article titled, Phase I Study of Oral Topotecan in Hematological Malignancies

Journal Articles

Development of Varicella-Zoster Virus Infection in Patients with Chronic Myelogenous Leukemia Treated with Imatinib Mesylate

Gloria N. Mattiuzzi, Jorge E. Cortes, Moshe Talpaz, James Reuben, Mary Beth Rios, Jianjin Shan, Dimitrios Kontoyiannis, Francis J. Giles, Issam Raad, Srdan Verstovsek, Alessandra Ferrajoli, Hagop M. Kantarjian

Clin Cancer Res (2003) 9 (3): 976–980.

Published: 01 March 2003

View article titled, Development of Varicella-Zoster Virus Infection in Patients with Chronic Myelogenous Leukemia Treated with Imatinib Mesylate

Journal Articles

Quantitative Polymerase Chain Reaction Monitoring of BCR-ABL during Therapy with Imatinib Mesylate (STI571; Gleevec) in Chronic-Phase Chronic Myelogenous Leukemia

Hagop M. Kantarjian, Moshe Talpaz, Jorge Cortes, Susan O’Brien, Stefan Faderl, Deborah Thomas, Francis Giles, Mary Beth Rios, Jianqin Shan, Ralph Arlinghaus

Clin Cancer Res (2003) 9 (1): 160–166.

Published: 01 January 2003

View article titled, Quantitative Polymerase Chain Reaction Monitoring of BCR-ABL during Therapy with Imatinib Mesylate (STI571; Gleevec) in Chronic-Phase Chronic Myelogenous Leukemia

NARROW

Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations

Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia

Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22

Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS

Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia

Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases

Abstract B22: Genome-wide methylation analysis reveals an independently validated CpG island methylator phenotype associated with favorable prognosis in acute myeloid leukemia.

Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens

Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia

The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia

Second-Generation Tyrosine Kinase Inhibitors: The Future of Frontline CML Therapy

Targeting DNA Methylation

The Prognostic Significance of Serum β₂ Microglobulin Levels in Acute Myeloid Leukemia and Prognostic Scores Predicting Survival: Analysis of 1,180 Patients

Phase I Study of Alternate-Week Administration of Tipifarnib in Patients with Myelodysplastic Syndrome

Important Therapeutic Targets in Chronic Myelogenous Leukemia

Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies

Phase I Study of Oral Topotecan in Hematological Malignancies

Development of Varicella-Zoster Virus Infection in Patients with Chronic Myelogenous Leukemia Treated with Imatinib Mesylate

Quantitative Polymerase Chain Reaction Monitoring of BCR-ABL during Therapy with Imatinib Mesylate (STI571; Gleevec) in Chronic-Phase Chronic Myelogenous Leukemia

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only